<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>White matter impairment is a feature of vascular <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The anti-<z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> <z:chebi fb="0" ids="8707">quetiapine</z:chebi> has been shown to enhance the therapeutic effects of anti-depressants on vascular <z:hpo ids='HP_0000716'>depression</z:hpo>, but the mechanism remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we found that 2 weeks of treatment with <z:chebi fb="0" ids="8707">quetiapine</z:chebi> prior to bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and reperfusion, in an animal model of vascular <z:hpo ids='HP_0000716'>depression</z:hpo>, resulted in reduced myelin breakdown and oligodendrocyte loss compared to placebo-treated mice on post-operative day (POD) 7 </plain></SENT>
<SENT sid="3" pm="."><plain>For late stage of recovery (POD40), <z:chebi fb="0" ids="8707">quetiapine</z:chebi> treatment resulted in enhanced oligodendrocyte maturation relative to placebo </plain></SENT>
<SENT sid="4" pm="."><plain>The results suggest that <z:chebi fb="0" ids="8707">quetiapine</z:chebi> is a potential intervention for oligodendrocyte damage and this may contribute to its anti-depressant effects through white matter protection in vascular <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
</text></document>